Exploring Biomarkers for Alzheimer's Disease.

Area of Science:

• Neuroscience
• Biomarker Discovery
• Geriatric Medicine

Background:

• Alzheimer's Disease (AD) is a leading cause of dementia in the elderly.
• Current diagnostic methods rely on cerebrospinal fluid (CSF) biomarkers (Aβ42, tau, p-tau) obtained via invasive lumbar punctures.
• There is a critical need for minimally invasive diagnostic markers for early AD detection.

Purpose of the Study:

• To review current and emerging blood-based biomarkers for Alzheimer's Disease.
• To highlight the advantages of blood serum and plasma over CSF for AD biomarker screening.
• To discuss the potential of novel technologies in identifying diagnostic and prognostic AD signatures.

Main Methods:

• Review of existing literature on Alzheimer's Disease biomarkers.
• Investigation of emerging technologies such as mass spectrometry, microarrays, and peptidomics.
• Analysis of various classes of blood-based markers including circulatory, amyloid, inflammatory, and oxidative stress markers.

Main Results:

• Blood serum and plasma offer a minimally invasive alternative to CSF for frequent and patient-friendly AD testing.
• Emerging technologies are crucial for discovering specific diagnostic and prognostic biomarkers.
• Several blood-based markers are under investigation for early AD detection and cognitive impairment prediction.

Conclusions:

• Developing minimally invasive, blood-based biomarkers is essential for early and efficient Alzheimer's Disease diagnosis.
• Utilizing advanced technologies will accelerate the discovery of reliable AD biomarkers.
• Future research should focus on validating these blood-based markers to improve patient management and clinical trial participation.